Decellularized Femoral Artery Allograft (Nexeon AVX) Prospective Registry
Recruiting now
Conditions studied: End-Stage Renal Disease
In brief
Post market registry to assess the safety and efficacy of a novel decellularized human femoral artery allograft (Nexeon AVX Decellularized Femoral Artery,
Key facts
- Study ID
- NCT05880537
- Run by
- LifeNet Health
- People needed
- 100
- Starts
- 2023-06-06
- Expected to finish
- 2027-12-15
- Last updated by the study team
- 2025-04-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Be male or female, ≥18 years of age at the time of graft placement
- Have a diagnosis of ESRD or renal dysfunction requiring hemodialysis
- Subject requires dialysis access to start or maintain dialysis treatment and placement of an AV access graft is a viable access option.
- Have the ability themselves, or through their legal guardian, to understand the requirements of the study, to provide written informed consent/assent as evidenced by signature on an informed consent form (ICF) approved by an institutional review board (IRB), and to agree to abide by the study restrictions and return to the site for the required assessments
- Have provided written authorization for use and disclosure of protected health information
You may not qualify if…
- Be participating in a study of another investigational drug or device
- Have a known sensitivity to any of the processing reagents utilized in the manufacture of this product such as antibiotics (Lincomycin, Polymyxin B, Ciprofloxacin, Meropenum, Gentamicin, or Vancomycin) and processing reagents (N-lauroyl sarcosine, Denarase and glycerol/glycerin)
- Have a history or evidence of severe cardiac disease, myocardial infarction within 6 months, ventricular arrhythmias, or unstable angina requiring continuing treatment
- Have a history or evidence of severe peripheral vascular disease in the upper extremities
- Have the inability or be unable or unwilling to follow the study visit schedule
- Have the presence of any condition that, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated
Where it is running
- Infirmary Heath — Mobile, Alabama, United States (enrolling)
- Olive View - UCLA Medical Center — Sylmar, California, United States (enrolling)
- Harbor-UCLA Medical Center — Torrance, California, United States (enrolling)
- Sentara Norfolk General Hospital — Norfolk, Virginia, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.